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Abstract
A type 2 vaccine-derived poliovirus (VDPV), differing from the Sabin 2 strain at 8.6% (78/
903) of VP1 nucleotide positions, was isolated from seawater collected from a seaport in
São Paulo State, Brazil. The P1/capsid region is related to the Sabin 2 strain, but
sequences within the 5'-untranslated region and downstream of the P1 region were derived
from recombination with other members of Human Enterovirus Species C (HEV-C). The two
known attenuating mutations had reverted to wild-type (A481G in the 5'-UTR and Ile143Thr
in VP1). The VDPV isolate had lost the temperature sensitive phenotype and had accumu-
lated amino acid substitutions in neutralizing antigenic (NAg) sites 3a and 3b. The date of
the initiating OPV dose, estimated from the number of synonymous substitutions in the cap-
sid region, was approximately 8.5 years before seawater sampling, a finding consistent with
a long time of virus replication and possible transmission among several individuals.
Although no closely related type 2 VDPVs were detected in Brazil or elsewhere, this VDPV
was found in an area with a mobile population, where conditions may favor both viral infec-
tion and spread. Environmental surveillance serves as an important tool for sensitive and
early detection of circulating poliovirus in the final stages of global polio eradication.
Introduction
The oral poliovirus vaccine (OPV), developed by Albert Sabin, has been effectively used for
years in the control of poliomyelitis and elimination of wild polioviruses (WPV). Through its
extensive use in mass vaccination campaigns, as part of the World Health Organization's
(WHO) Global Polio Eradication Initiative (GPEI), it was possible to reduce the annual global
incidence of polio from hundreds of thousands of cases to less than 70 in 2015, and now the
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WPV circulation is restricted to only two countries, Afghanistan and Pakistan (http://www.
polioeradication.org/Dataandmonitoring/Poliothisweek.aspx).
Although OPV presents many advantages (easy administration, low cost, effective intestinal
immunity and durable humoral immunity), Sabin strains are inherently genetically unstable
[1, 2]. Due to the plasticity and rapid evolution of poliovirus genomes during replication in
human gut, the strains evolve by reversion of known attenuating mutations and recombination
with other members of Human Enterovirus C Species (HEV-C), leading to phenotypic changes
and an increase in neurovirulence [3–6]. As a consequence of the genetic instability of OPV
strains, vaccine-derived polioviruses (VDPV) have emerged on occasion in immunodeficient
patients or under conditions of low population immunity, low vaccine coverage, poor sanita-
tion and tropical conditions [7–9].
VDPVs are vaccine-related isolates whose genetic divergence from the parental OPV strains
indicates prolonged replication or circulation [10,11]. Gaps in vaccination coverage may allow
for circulation and antigenic drift of OPV strains. Type 1 and type 3 isolates that are>1.0%
divergent and type 2 isolates that are>0.6% divergent in VP1 sequences from the correspond-
ing Sabin strain are classified as VDPVs [12]. Ultimately, VDPV are particularly important for
GPEI strategies, since the divergent strains regained the ability to cause paralytic polio in
humans and the potential for sustained circulation, similar to wild-type virus, with a direct
impact on polio eradication [1,10].
VDPVs are categorized as: 1) Circulating VDPVs (cVDPV), related to person-to-person
transmission, 2) Immunodeficiency-associated VDPVs (iPVDV), isolated from individuals
with primary immunodeficiency, and 3) Ambiguous VDPVs (aVDPV), which are isolates that
cannot be classified definitively because they have no known source [10,12]. In recent years, 24
cVDPV outbreaks were identified in 21 countries, resulting in more than 750 cases of paralytic
poliomyelitis [13].
Brazil has a decades-long record of elimination of WPV transmission, and no report of
wild-type paralytic poliomyelitis since 1989 [14]. In January 2014, a highly evolved type 2
VDPV was isolated from seawater, during environmental surveillance in São Sebastião Seaport,
located on the north coast of São Paulo State, in the Southeast of the country. This seaport is
Brazil’s biggest port for liquid bulks, handling 26% of all of Brazil’s liquid cargos and counting
with a high flow of vessels and people from all over the world. No VDPV had been reported
from the environment or clinical samples in the Brazilian territory before or after this event,
and no paralytic cases were linked to this isolate. The origin of the virus and the shedding indi-
vidual are unknown, and calculations indicate that the original Sabin dose was given more than
8 years ago. In this report, we describe the genome characterization, phenotypic features and
phylogenetic analysis of this highly divergent virus, and emphasize the need for sustained envi-




L20B (NIBSC Accession No. 081102), RD (NIBSC Accession No. 081003) and HEp-2 (NIBSC
Accession No. 740502) cell lines were provided by the WHO Global Polio Laboratory Network
(GPLN) and used for virus isolation. The Oral Poliovaccine Sabin Type 2 reference strain
(NIBSC code 01/530) was also provided by WHO.
The Environmental Company of the São Paulo State (CETESB) is the state government
agency responsible for diagnosis and monitoring of environmental quality at São Paulo State,
Brazil. CETESB works in the field of Environmental Virology for about 40 years and since
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1999 develops a Surveillance Program for Enterovirus in collaboration with the Center of Epi-
demiological Surveillance of São Paulo State. The surveillance is based on bi-weekly routine
examination of sewage samples from potential points of foreign people such as international
airport and seaports, and from wastewater treatment plants. All poliovirus isolated are referred
to the Enterovirus Laboratory at Oswaldo Cruz Foundation in Rio de Janeiro, Brazil (WHO
Regional Reference Laboratory) for further characterization.
Among its activities, CETESB conducts environmental poliovirus surveillance through rou-
tine sampling and laboratory analysis of seawater from the pier in São Sebastião seaport at São
Paulo State cost. No specific permissions are required for developing these activities at this
location. This field study did not involve endangered or protected species.
Sampling (Moore swab), concentration (organic flocculation) and processing (chloroform
clarification) of samples were performed as described in Sattar &Westwood [15] and USEPA
[16]. Poliovirus was isolated according to the WHO alternative test algorithm [17] and submit-
ted to intratypic differentiation using WHO guidelines for Polio laboratories [18].
Individual isolates had been named according to the following convention: PV (poliovirus)
followed by the number denoting the type/isolate number/3-letter country followed by the year
of isolation (e.g. PV2/44624/BRA2014). For use in this report, the type 2 VDPV isolate name
has been shortened to 44624.
Primary characterization of isolate 44624
The sequences for all primers used in this study are described in S1 Table. Initial virus charac-
terization (intratypic differentiation) was performed using real-time reverse transcription–
polymerase chain reaction (rRT-PCR) nucleic acid amplification, provided by the Centers of
Disease Control and Prevention–CDC, according to GPLN guidelines [12]. The VDPV screen-
ing assay is targeted to nucleotide substitutions that typically revert to the parental WPV
sequence during replication of OPV in the human intestine [19]. Viral RNA was extracted
from an aliquot of 140μL of L20B cell culture supernatant, using QIAamp Viral RNAMini Kit
(Qiagen, Hilden, Germany) and stored at -80°C for further use. Two different reactions of
One-Step Real-time PCR were successively performed in a ABI 7500 Real Time machine
(Applied Biosystems, Carlsbad, CA, USA): a Real-time ITD Test, using six set of primers,
namely: Pan-Enterovirus, Pan-Poliovirus, Serotype 1, Serotype 2, Serotype 3, and Sabin Multi-
plex (1, 2 and 3); and a Real-time VDPV Screening Assay, targeting regions in Sabin 1, 2 and 3
known to be involved in reversion to a neurovirulent phenotype. For all Real-Time PCR reac-
tions, the Ct value cutoff for positive reactions was cycle 30.
Candidate VDPVs identified by rRT-PCR screening were sequenced in the VP1 gene (903
nt) for definitive analysis [17,18]. cDNA was prepared from 10 μL of stock viral RNA using 1μl
of Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA), primed by S2
7439R_Sal (described in S1 Table), and performed at 42°C for 50 minutes, followed by 15 min-
utes of enzyme inactivation at 70°C. The RNA in the RNA-DNA dimer was specifically
degraded by the action of 1μL of Ribonuclease H (Promega, Madison, WI, USA) at 37°C for 30
minutes. The VP1 coding region was amplified and sequenced using the primers Y7/Q8 [20].
The PCR product was purified using QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany),
and cycle sequencing reactions were carried out using BigDye terminator chemistry version 3.0
(Applied Biosystems, Carlsbad, CA, USA) on an ABI 3130XL instrument.
Cross-reactivity using polyclonal antibodies
In order to determine the antigenic characteristics of isolate 44624, a micro neutralization test
was performed according to WHO recommendations [21], using serotype-specific PV1, PV2
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and PV3 polyclonal antibodies and RD cells. Briefly, two-fold dilutions of polyclonal serum
specific for each serotype (WHO/EPI/POLIO) (from 1:2 to 2048) in Eagle-Earle medium were
incubated with 100 TCID50 of each poliovirus serotype at 37°C for 1 h. One hundred microli-
ters of Eagle-Earle medium with 2% Fetal Calf Serum, containing 20000 RD cells, were added
to the neutralizing mixture (100 ml). Plates were incubated at 37°C for 7 days, and examined
for the appearance of CPE with an inverted microscope. Neutralizing antibody titers were cal-
culated by the Karber formula, and expressed as the highest serum dilution neutralizing 50% of
the infected cultures.
Full-length genome amplification
The complete genome of VDPV2 44624 was sequenced for high-resolution analysis. Two long-
distance PCR reactions were performed by using the Expand Long Template PCR System
(Roche). The two sets of sense/antisense primer pairs 001F_Hind/Q8 and Y7/S2 7439R_Sal
were used to amplify two overlapping fragments of 3.57 kb and 5.28 kb, respectively. The PCR
mixture for each reaction consisted of 3 μL of cDNA, 300nM sense primer, 300nM antisense
primer, 350μM dNTP’s, 5μL 10x PCR buffer 3 with MgCl2, 0,75μl Expand Long Template
enzyme mix and DNase/RNase-free water into a 50μl final volume. The cycling parameters for
the 3.57kb fragment were 94°C for 2min, 10 cycles of 94°C for 15s, 50°C for 30s and 68°C for
3:30min, followed by 25 cycles of 94°C for 15s, 58°C for 30s and 68°C for 3min30s, with a final
extension at 68°C for 10min. For the 5.28kb fragment, the same reaction parameters were used,
except for extension periods of 4 minutes and 30 seconds.
The two fragments were purified using QIAquick Gel Extraction Kit (Qiagen, Valencia, CA,
USA). Cycle sequencing reactions were carried out using BigDye terminator chemistry version
3.0 (Applied Biosystems, CA, USA), using the primers described in S1 Table. Sequencing was
bi-directional, and every nucleotide position was sequenced at least once from each strand. The
3’-end segment sequences were determined by using the 3’ RACE System for Rapid Amplifica-
tion of cDNA Ends (Life Technologies, USA). Isolate 44624 was also referred to the Centers for
Disease Control and Prevention (Atlanta, USA).
The nucleotide and amino acid sequences of isolate 44624 were aligned with the Sabin 2 ref-
erence strain (GenBank accession number AY184220) using ClustalW, and molecular evolu-
tionary analyses were performed using MEGA program v6.0 [22]. After analysis of mutational
sites, for visualization of the observed amino acid substitutions, the amino acid positions were
placed in the 3-dimensional structure model of poliovirus capsid protomer, based on x-ray
crystallographic analysis of type 2 poliovirus strain Lansing (PDB ID: 1EAH) [23] using the
software Swiss-PdbViewer [24]. The GenBank accession number of isolate 44624 complete
genome sequence is KU372652.
Time of divergence of the isolate 44624 from the original Sabin 2 strain
The time interval between the date of OPV administration and the data of sampling of the
VDPV2 44624 was estimated from the nucleotide divergence between the P1/capsid and VP1
sequences of the virus 44624 and Sabin 2 reference strain (GenBank accession number
AY184220). The other parts of the genome (containing potential recombination regions) were
not included in this analysis. Maximum-likelihood estimates of synonymous substitutions per
synonymous sites (Ks) and nonsynonymous substitutions per nonsynonymous sites (Ka) were
obtained following a modified version of Goldman-Yang codon model of evolution [25] as
implemented in MBEToolbox [26]. Total number of substitutions per site (Kt) was estimated
using the T92 model of nucleotide evolution implemented in MBEToolbox [27].
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Recombination events
The aligned full-length genome sequences of isolate 44624 and members of Human Enterovi-
rus C Species (GenBank accession numbers for reference strains Sabin 1 (AY184219), Sabin 2
(AY184220), Sabin 3 (AY184221), Coxsackie virus 1 (CVA1) (AF499635), CVA11 (AF49
9636), CVA13 (AF465511), CVA17 (AF499639), CVA19 (AF499641), CVA20 (AF499642),
CVA21 (AF465515 and D00538), CVA24 (EF026081), Enterovirus C96 (HQ415759), Entero-
virus C99 (KJ857508), Enterovirus 104 (JX982259) and Enterovirus C109 (GQ865517)) were
subjected to recombination analysis. The RDP4 algorithm package was used to detect homolo-
gous recombination events [28] using the default parameters for the methods GENECOV [29],
Bootscan [30], Chimaera [31], MaxChi [32], SiScan [33], 3Seq [34] and RDP [35]. As selection
criteria for statistical analysis, a putative recombination event was referred to subsequent analy-
sis only when it was consistently identified by at least three of these seven RDP algorithms [36].
The P-value cutoff was chosen as 0.05 and the best signals for recombination are associated
with the lowest P-values, which indicates the approximate likelihood for the occurrence of
exchange of sequences between genomes (recombination) rather than the probability of con-
vergent evolution of the sequences.
Phylogenetic analysis
For analysis of divergence and evolution of Brazilian isolate 44624, a phylogenetic tree was con-
structed for complete VP1 sequences (903nt), using Mega software package, version 6.0 [22].
The 44624 VP1 sequence was aligned to VP1 sequences of Sabin 2 (GenBank accession number
AY184220) and a set of divergent type 2 VDPVs identified between 1998–2015, in China (Gen-
Bank accession numbers KJ419273-KJ419277, AY948201, HM107832–HM107835) [37–39],
Egypt (GenBank accession numbers AF448782 and AF448783) [40], Madagascar (GenBank
accession numbers HF913426-HF913428, AM084223, AM084225) [41, 42], Nigeria (GenBank
accession numbers JX274980, JX275085, JX274985, JX275162, JX275380, DQ890388) [43, 44],
Israel (GenBank accession numbers AJ288062, AM040035-39, AM056049-50, AM158275-6,
AM292219-21) [45], Slovakia (GenBank accession numbers JX913541-JX913553, JX913635-
913647) [46] and Estonia (GenBank accession numbers KC784367-KC784371) [47].
The evolutionary history was inferred using the Maximum Likelihood Method based on the
Kimura-2 parameters [48], the best-fit substitution model indicated by Mega6 software [22]
for this dataset. All positions containing gaps and missing data were eliminated.
Temperature Sensitivity
Reproductive capacity at different temperatures (RCT marker) of isolate 44624 was evaluated
on monolayers of RD cells in 6-well plates by an RCT test, in comparison to the Sabin 2 refer-
ence strain. A total of 6.5 x 105 cells were seeded per well, and after attachment, 200μL of virus
stocks were inoculated and incubated separately at 36.5°C or 40°C for virus absorption for 1
hour, after which the cells were washed, and 3ml of maintenance medium were added per well,
followed by incubation at 36.5°C or 40°C, separately. After 8, 24 and 48 h, the cells were har-
vested, and the TCID50s were calculated in 96-well plates. More than 2 logarithms reduction
of the titers at different temperatures was considered to be temperature sensitive [49, 50]. In
order to minimize experimental error, the assay was conducted three times.
One-step growth curve
One-step growth curve experiments were performed in RD cells at 36.5°C and 40°C, with a
multiplicity of infection of 10 as determined by TCID50 infectivity titration of virus stocks on
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RD cells. The used protocol was previously described in [51]. Briefly, 2 x 104 RD cells were
added into each well of fourteen 96-well culture plates. After attachment, isolate 44624 and
Sabin 2 reference strains were inoculated into three replica wells of 96-well cell culture plates.
The plates were incubated at 37°C for 2 hours, and the cells were washed twice with 300 μL of
Eagle-Earle medium to remove unbound virus. Then, 100 μL of Eagle-Earle was added per well
and plates were incubated at 36.5°C or 40°C for 0, 2, 4, 6, 8, 10 and 12 hours. The plates were
subjected to three consecutive freeze-thaw cycles and the viral titers were determined by the
TCID50 assay on RD cells at 36.5°C for each time point. In order to guarantee reproducible
results, the titration was repeated three independent times for each tested condition.
Results
Preliminary Characterization of the Isolate
The virus 44624 was isolated from seawater collected in São Sebastião Seaport, São Paulo, in
January 2014. Diagnostic rRT-PCR proved that it is a type 2 VDPV. Compared to Sabin 2 orig-
inal strain, the isolate 44624 showed 8.6% nucleotide divergence (78/903 nt) in VP1. Among
the 9 amino acid changes found, the substitution Ile143Thr, located inside the VP1 DE-loop, is
a common substitution in VDPV2 isolates [1, 45, 52], and characterizes the loss of a known
major signature of Sabin 2 attenuation [1]. No recombination event was found in the VP1
region.
Complete sequence of isolate 44624
The full-length genome of isolate 44624 contains 7439 nucleotides plus the polyA tail, with an
open reading frame (ORF) of 2207 amino acids. In a comparative analysis with available Gen-
Bank sequences, the closest relative in the capsid region appeared to be Sabin 2 strain, although
the genetic and amino acid divergences between strains were noteworthy (Table 1). Although
the P1 region/capsid is colinear with that of Sabin 2, regions of the 5´-UTR, P2, P3 and 3
´-UTR contain sequences derived from other HEV-C Enterovirus.
The 5'-UTR region of 44624 and Sabin 2 have the same size (747 nt.), but differ greatly from
each other in the hyper variable region of the 5’-UTR (approximately the last 100nt. before the
initiation codon) due to a large number of nucleotide substitutions, insertions and deletions.
Position 481 in the 5’-UTR, another major determinant of the attenuated phenotype of Sabin
2, had reverted from A in the Sabin 2 to G found in WPV strains. This transition is frequently
observed in VDPV-associated paralytic poliomyelitis cases and is correlated with neuroviru-
lence and efficiency of genomic translation [1, 53].
The P1 capsid region contains a total of 188 nt. substitutions, and 14 predicted amino acid
substitutions. The mutational pattern of the capsid was characterized by a preponderance of
synonymous substitutions (92.02%) over nonsynonymous mutations (7.98%). Nonsynon-
ymous mutations identified in the capsid protomer are show in Fig 1, while the reconstruction
of a capsid pentamer (intern and extern view) of isolate 44624 is available in S1 Fig.
Only synonymous mutations were found in VP4. VP2 accounts for 2 nonsynonymous
mutations, Thr45Ser and Lys152Arg, the former representing a reversion to the amino acid res-
idues found in both MEF-1 (GenBank accession number AY238473), a laboratory reference
wild-type PV2 strain, and Lansing (GenBank accession number M12197), a wild-type PV2
strain associated with fatal paralytic disease in mice after intracerebral inoculation [54–56].
VP3 coding region has three nonsynonymous mutations (Ser73Asn; Thr75Ala; Ile103Val).
The substitutions in amino acids 73 and 75 of VP3 are located in NAg 3a and 3b of PV serotype
2, respectively (Fig 2). Another modification in the NAg region was found in VP1 coding
region, also in NAg3a (Thr291Ala). VP1 coding region of isolate 44624 contains other 7
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nonsynonymous substitutions (Met5Val; Val10Ile; Glu11Asp; Pro9Leu; Thr10Ala; Val215Ile;
Ile257Val). In spite of amino acid substitutions inside and near NAg sites, micro neutralization
assay with polyclonal PV1-, PV2- and PV3-specific antisera showed that isolate 44624 was
completely neutralized by polyclonal PV2-specific antisera, and had no cross-neutralization
with PV1- and PV3-specific antisera.
The cis-acting replication element (cre element, nt. 4443–4503) in the 2C coding region
contained 9 substitutions in comparison with the Sabin 2 reference sequence. Importantly, the
Sabin 2 conserved AAACAmotif, placed inside the loop of the cre structure, was substituted by
an AAGCAmotif in the isolate 44624. The AAGCA motif is found in the type 2 WPV cre ele-
ment [57, 58].
Analyses of putative recombination events
The complete genome of isolate 44624 and other polio and non-polio HEV-C species were ana-
lyzed by using the algorithms available in the RDP package software in search for putative
recombination break points. We were able to find five statistically significant (P-value< 0.05)
putative recombination events between 44624 genome and other Enterovirus HEV-C reference
sequences (Table 2), what strongly indicates that isolate 44624 was a product of recombination
between Sabin 2 and other HEV-C viruses.
The reference sequences of Sabin 2 (AY184220), Sabin 3 (AY184221), CVA11 (AF499636),
CVA13 (AF465511), CVA20 (AF499642) and CVA24 (EF026081) were presented as putative
parental strains of isolate 44624 by the RDP algorithms (P-value< 0.05). However, it is













5'-UTR 747 128 82.86 NA NA NA 5’-UTR hyper variable region;
A481G
P1 region 2637 192 92.72 879 14 98.41
VP4 207 13 93.71 69 0 100
VP2 813 46 94.34 271 2 99.26 Thr45Ser; Lys152Arg
VP3 714 52 92.71 238 3 98.74 Ser73Asn; Thr75Ala
VP1 903 81 91.03 301 9 99 Ile143Thr; Thr291Ala
P2 region 1725 153 91.13 575 15 97.39
2A 447 36 91.94 149 4 97.31
2B 291 57 80.41 97 4 95.88
2C 987 60 93.92 329 7 97.87 “cre element”
P3 region 2259 175 92.25 753 14 98.14
3A 261 47 81.99 87 4 95.40
3B 66 11 83.33 22 1 95.45
3C 366 45 87.70 122 2 98.36
3D 1557 72 95.37 519 7 98.66
3´-UTR 71 2 97.18 NA NA NA
Entire genome 7439 650 91.26 2207 43 98.05
*The figures are for isolate 44624.
**The ORF length was identical for both strains.
NA, not applies.
doi:10.1371/journal.pone.0152251.t001
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difficult to precisely determine the parental strains of the isolate 44624 because sometimes two
different pairs of major/minor parental strains were predicted with statistical significance for
the same genomic region (see predicted recombination events 2 and 3 for VP4-to-VP1 capsid
sequences and events 4 and 5 for 2A-to-3C non-structural gene sequences, as described in
Table 2).
No close relationship was found by comparing isolate 44624 with sequences belonging to
Enterovirus HEV-A, -B or–D species (data not shown). These results suggest that the donors
Fig 1. Amino acid substitutions in the capsid protomer of isolate 44624. VP1, VP2, VP3 and VP4 are represented as a 3-dimensional structured
protomer. The image was generated using the software Swiss-PdbViewer [24], based on X-ray crystallographic analysis of type 2 poliovirus strain Lansing
(Protein Data Bank accession number 1EAH.pdb) [23]. Colour codes: Substitutions at known antigenic sites, brown. Substitutions elsewhere, pink. The BC-
loop of VP1 is not visible in this model.
doi:10.1371/journal.pone.0152251.g001
Fig 2. Alignment of amino acids residues of neutralizing antigenic (NAg) sites for Sabin 2 (GenBank accession number AY184220) and isolate
44624. Amino acid positions are numbered according to Sabin 2 NAg1 (VP1 88–106), NAg2 (VP2 163–169; VP2 268–270; VP1 220–225), NAg3a (VP3 54–
61; VP3 70–74; VP1 286–291) and NA3b (VP2 71–73; VP3 75–79).
doi:10.1371/journal.pone.0152251.g002
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of non-capsid sequences of isolate 44624 were unidentified strains possibly belonging to
Enterovirus HEV-C species. A schematic representation of the proposed mosaic genome of
44624 is presented in Fig 3.
Time of divergence of the isolate 44624 from the Sabin 2 strain
In order to estimate the time of divergence of the isolate 44624 from the original Sabin 2 strain
(GenBank accession number AY184220), the approximate evolution time of isolate 44624 rela-
tive to Sabin 2 was calculated for both complete P1/capsid and VP1 sequences. It would be an
indication of both the date of initial OPV administration and the time of replication of the iso-
late 44624.
The estimated proportions for Ks/dS were 0.249 and 0.301 synonymous substitutions per
synonymous sites for P1/capsid and VP1 sequences, respectively. The values of 0.008 (P1/cap-
sid) and 0.015 (VP1) were found for nonsynonymous substitutions per nonsynonymous sites
(Ka/dN), and the Kt values were estimated to be 0.077 and 0.094 total substitutions per sites for
P1/capsid and VP1 sequences, respectively. The evolution time of isolate 44624 relative to
Sabin 2 strain, calculated for the entire P1 region, is about 8.5 years (using Ks and Kt clocks),
indicating the long time of replication of the isolate 44624 since the OPV initial dose. The cal-
culated value for dN/dS, which can be used as an indicator of selective pressure acting on a pro-
tein-coding gene, is 0.033 for P1/capsid (0.051 for VP1 sequence), what is lower than the dN/
dS values estimated for iVDPVs datasets (J. Jorba, personal communication).
Phylogenetic Analysis
The phylogenetic relatedness among isolate 44624 and other VDPV2 sequences available in
GenBank was evaluated with MEGA6 software [22]. Phylogenetic investigation revealed no
close relationship with the other VDPV analysed (Fig 4); therefore, the geographic origin of the
Brazilian VDPV isolate remains unknown.
RCTmarker test
The temperature sensitivity assay showed that there is no significant difference between titer of
isolate 44624 at 36.5°C and at 40°C (Table 3), signifying that VDPV2 44624 had lost the attenu-
ated temperature-sensitive (ts) phenotype and can efficiently replicate at elevated temperatures,
similarly to WPV. For the Sabin 2 reference strain, the>2 log titer difference at 36.5°C and at
40°C is consistent with the ts phenotype of Sabin strains. Tests carried out in triplicate showed
similar results.
Fig 3. Schematic representation of the genome of recombinant aVDPV 44624, isolated in Brazil. Non-
vaccine sequences (HEV-C species) are represented in light blue. Highly mutated Sabin 2 regions are
represented in gray.
doi:10.1371/journal.pone.0152251.g003
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One-step growth curve
The growth rate and virus yields of isolate 44624 were compared with those of Sabin 2 in one-
step growth curve experiments at 36.5°C and 40°C in RD cells (Fig 5). The isolate 44624
showed different growth kinetics from that of its Sabin 2 progenitor. At 36.5°C, 44624 had
faster growth rates between 4 and 6 h p.i., presenting a curve slope essentially steeper than
Sabin 2 strain, what indicates a faster growth rate at the exponential phase of the replication
cycle in RD cells. Also, Sabin 2 had a lower final titer at 12 h p.i. At 40°C, 44624 again grew
Fig 4. Phylogenetic analysis of VP1 sequences of isolate 44624 and a set of type 2 VDPV isolated between 1998 and 2015. Evolutionary distances
were computed using Maximum Composite Likelihood method and Neighbor-joining tree. Consensus from 1000 bootstrap replicates is shown.
doi:10.1371/journal.pone.0152251.g004
Table 3. Reproductive capacity of VDPV2 isolate 44624 and Sabin 2 strain at different temperatures (RCTmarker). The RCT value is defined as the
difference between the log 10 virus titer of the viral stock measured at the optimal temperature 36,5°C and supraoptimal temperature 40°C. The values are
expressed as log 10 TCID50 / 0,1ml. Virus were considered thermosensitive if the ΔRCT value was greater or equal to 2, and thermo resistant when RCT
value was inferior to 2.00.
Virus Hours p.i. Titer at 36,5°C Titer at 40°C Log titer reduction Δ
44624 8h 7.9 7.7 0.2
24h 7.9 7.9 0.2
48h 8.1 7.6 0.5
Sabin 2 8h 7.9 3.6 4.3
24h 7.8 3.8 4.0
48h 7.7 3.7 4.0
doi:10.1371/journal.pone.0152251.t003
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more efficiently between 4 and 6 h. p.i., presenting a result similar of those at 36.5°C, and still a
better performance than Sabin 2 at 36,5°C. As expected, Sabin 2 presented lower efficiency of
replication at 40°C (ts phenotype), and the lowest final titer. As indicated in RCT test, isolate
44624 had lost its temperature sensitivity, and replicated equally well at both tested tempera-
tures. Triplicate tests showed similar results.
Fig 5. One-step growth curve analysis of isolate 44624 in comparison with Sabin 2 in RD cells.Cells were infected at a MOI of 10 and incubated at 37
or 40°C. Total virus production at different times (0-12h) post-infection were determined by TCID 50 assays on RD cells. Each point represents the mean
+ standard deviation of virus titers from three different experiments.
doi:10.1371/journal.pone.0152251.g005
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Discussion
This study aimed to assess the molecular and phenotypic characterization of a highly divergent
type 2 ambiguous VDPV (aVDPV) isolated from seawater at the São Sebastião Seaport, located
on the northern coastline of São Paulo state. The estimates of evolution time of isolate 44624,
calculated from the nucleotide divergence from Sabin 2 original strain (AY184220), indicate
that the isolate 44624 has been circulating for at least 8.5 years. At the time of 44624 isolation,
the overall coverage with 3 doses of oral polio vaccine for children under 1 year old was about
~100% for both Brazil and the town of São Sebastião (Data available at http://pni.datasus.gov.
br). The episode was not associated with reported cases of paralytic poliomyelitis.
The last report of indigenous transmission of WPV in Brazil dates back to 1989 [14]. To
begin the withdrawal of OPV from the vaccination calendar, Brazil changed to a combined vac-
cination schedule (2 IPV doses followed by 2 OPV doses) in 2012. Since OPV has been admin-
istered in the country for decades, the detection of Sabin strains from the environment is a
frequent event. However, it was the first time that a VDPV strain has been reported in Brazil.
The isolate 44624 has no close relationship with either other polio or non-polio Enterovi-
ruses isolated in Brazil before or after this event. Because the seaport is subject to a large flow of
people from around the world, it is likely to be an imported virus, with no establishment of a
continuous transmission chain in the local population. However, the evidence is insufficient to
exclude other possibilities (like the existence of a local chronic excretor).
During evolution, cVDPV and iVDPV are under distinct biological selective pressures,
which result in differences in key properties [10]. Isolate 44624 likely has a cVDPV origin, due
to the presence of recombination breakpoints with non-vaccine HEV-C Enteroviruses, which
frequently occurs during poliovirus circulation and suggests the occurrence of person-to-per-
son transmission [59, 60]. Although it is not mandatory for cVDPV emergence, vaccine/non-
vaccine recombination appears to facilitate the replacement of attenuating sequences in a single
event [61]. Moreover, iVDPV isolates are widely known to have extensive antigenic variability
(many mutations in or near NAg sites), which is not common in cVDPV strains [62] and was
not observed in isolate 44624.
The A481G change in the 5’-UTR, along with the amino acid substitution Ile143Thr in VP1
are well known to be the two major determinants of the attenuated phenotype of Sabin 2 [63,
64], and both sites had reverted to the wild-type nt. in isolate 44624. These substitutions are
frequently found in VDPV [40, 41, 65] and many OPV-like isolates [63, 66–68], which is prob-
ably indicative of the intense selective pressure against these attenuating alleles as OPV repli-
cates in the human intestine [66].
The 44624 recombinant genome has kept only the P1 region/capsid from the original Sabin
2 strain, which determines the antigenic properties of the viral serotype, while all other parts of
the genome are derived from recombination with other HEV-C species. As presented in
Table 2, between the evaluated sequences of HEV-C species, the strains that statistically are
more likely to be parental strains for isolate 44624 are Sabin 2 (AY184220), Sabin 3
(AY184221), CVA11 (AF499636), CVA13 (AF465511), CVA20 (AF499642) and CVA24
(EF026081), but the parental strains could not be precisely determined because there are more
than one statistically acceptable event for the majority of putative recombination events. It is
possible that more accurate predictions would be achievable through analysis of sequences cur-
rently in circulation, instead of reference strains. The absence of a sequence database from
HEV-C species currently circulating in Brazil and the impossibility to test the large quantity of
HEV-C sequences available at the GenBank were limiting factors of this analysis.
Likewise, phylogenetic analysis did not identify closely related VDPV sequences for isolate
44624. The impracticality to screen all Sabin 2-related sequences available in GenBank and the
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huge amount of non-deposited sequences were also limitation steps of this analysis. Therefore,
the origin of isolate 44624 remains unknown.
The findings presented here indicate that the aVDPV isolate 44624 has been subjected to a
long period of circulation and probably person-to-person transmission [10]. The presence of
highly drifted, neurovirulent strains in the environment is a potential risk for transmission and
spread of pathogenic polioviruses. The findings of this study reiterate the environmental sur-
veillance as a sensitive tool for detection of poliovirus at low levels of circulation and in the
absence of paralytic poliomyelitis cases [69–73]. Therefore, the authors encourage the enhance-
ment and expansion of environmental surveillance to help identify any residual transmission
in endemic areas and to provide early indication of new importations or emergence of VDPV
strains, in order to deliver a world free of polio in the years to come.
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type 2 poliovirus strain Lansing (PDB ID: 1EAH). Panel A, view from outside of virion; Panel
B, view from inside the capsid wall. Locations of amino acids substituted in isolate 44624 in
comparison to Sabin 2 are indicated. Colour codes: VP1, white; VP2, blue; VP3, cyan; VP4,
red. Substitutions at know antigenic sites, brown. Substitutions elsewhere, magenta. The BC-
loop of VP1 is not visible in this model.
(PDF)
S1 Table. Primers used for complete genomic sequencing of isolate 44624.
(DOCX)
Acknowledgments
The authors would like to thank the technical assistance of Amanda de M. Neves and Jaqueline
Silva from Enterovirus Laboratory and Suzi C. Garcia and Vilma M.B. dos Santos from
CETESB Virology Laboratory.
Author Contributions
Conceived and designed the experiments: EES MIZS CCB KMSMC. Performed the experi-
ments: KMSMC FMBMRFB QC EMH. Analyzed the data: KMSMC FMB JJ EES. Contributed
reagents/materials/analysis tools: KMSMC JJ. Wrote the paper: KMSMCMIZS CCB EES.
References
1. Kew OM, Sutter RW, de Gourville EM, DowdleWR, Pallansch MA. Vaccine-derived polioviruses and
the endgame strategy for global polio eradication. Annu Rev Microbiol 2005 Oct; 59:587–635. PMID:
16153180
2. Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine–live. In: Plotkin SA, Ornstein WA, Offit
PA, editors. Vaccines. London: W. B. Saunders; 2013. p. 598–645.
3. Equestre M, Genovese D, Cavalieri F, Fiori L, Santoro R, Perez Bercoff R. Identification of a consistent
pattern of mutations in neurovirulent variants derived from the Sabin vaccine strain of poliovirus type 2.
J Virol 1991 May; 65(5):2707–10. PMID: 1850043
4. Famulare M, Chang S, Iber J, Zhao K, Adeniji JA, Bukbuk D, et al. Sabin vaccine reversion in the field:
a comprehensive analysis of Sabin-like poliovirus isolates in Nigeria. J Virol 2015 Oct. doi: 10.1128/
JVI.01532-15
5. Gnanashanmugam D, Falkovitz-Halpern MS, Dodge A, Fang M, Wong LJ, Esparza M. Shedding and
reversion of oral polio vaccine type 3 in Mexican vaccines: comparison of mutant analysis by PCR and
Type 2 VDPV Isolated in Brazil
PLOS ONE | DOI:10.1371/journal.pone.0152251 March 28, 2016 14 / 18
enzyme cleavage to a real-time PCR assay. J Clin Microbiol 2007 Aug; 45(8):2419–2425. PMID:
17581940
6. Otelea D, Guillot S, Furione M, Combiescu AA, Balanant J, Candrea A, et al. Genomic modifications in
naturally occurring neurovirulent revertants of Sabin 1 poliovirus. Dev Biol Stand 1993 78:33–38.
PMID: 8099049
7. Bellmunt A, May G, Zell R, Pring-Akerblom P, VerhagenW, Heim A. Evolution of poliovirus type 1 dur-
ing 5.5 years of prolonged enteral replication in an immunodeficient patient. J Clin Microbiol 1998 Dec
20; 265(2):178–84.
8. Kew OM, Sutter RW, Nottay BK, McDonough MJ, Prevots DR, Quick L, et al. Prolonged replication of a
type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 1998 Oct; 36
(10):2893–9. PMID: 9738040
9. Kew OM, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, et al. Outbreak of poliomyelitis in His-
paniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002 Apr 12; 296
(5566):356–9. PMID: 11896235
10. Burns CC, Diop OM, Sutter RW, KewOM. Vaccine-derived polioviruses. J Infect Dis 2014 210 (suppl
1):S283–S293. doi: 10.1093/infdis/jiu295 PMID: 25316847
11. Diop OM, Burns CC, Sutter RW,Wassilak SG, Kew OM. Update on vaccine-derived poliovirus–world-
wide, January 2014-March 2015. MMWMorb Mortal Wkly Rep 2015 Jun 19; 64(23):640–646.
12. Diop OM, Burns CC, Wassilak SG, Kew OM. Update on vaccine-derived poliovirus-worldwide, July
2012-December 2013. MMWRMorb Mortal Wkly Rep 2014 Mar 21; 63(11):242–248. PMID: 24647401
13. Global Polio Eradication Initiative. Vaccine-associated paralytic polio (VAPP) and vaccine-derived
poliovirus (VDPV). Fact Sheet–February 2015. [Internet] Available from: http://www.who.int/
immunization/diseases/poliomyelitis/endgame_objective2/oral_polio_vaccine/
VAPPandcVDPVFactSheet-Feb2015.pdf
14. World Health Organization. Detection of poliovirus in sewage, Brazil. 2014. [Internet] Available from:
http://www.who.int/csr/don/2014_6_23polio/en/
15. Sattar SA, Wetwood JCN. Isolation of apparently wild strains of poliovirus type 1 from sewage in the
Ottawa area. CMA Journal 1977 Jan 116:25–7.
16. USEPA 2003. Environmental Regulations and Technology. Control of pathogens and vector attraction
in sewage sludge. EPA/525/R-092/013. Jul 2003.
17. World Health Organization. Polio Lab Network. Quartely update. New test algorithm to be implemented
in 2007. Vol. XXXIII (issue 4): 2006.
18. World Health Organization. Polio Laboratory Manual. 4th edition. Geneva. Switzerland. 2004.
19. Kilpatrick DR, Ching K, Iber J, et al. Identification of vaccine-derived polioviruses using dual-stage real-
time RT-PCR. J Virol Methods 2014 Mar; 197:25–8. doi: 10.1016/j.jviromet.2013.11.017 PMID:
24321704
20. Rico-Hesse R, Pallansch MA, Nottay BK, Knew OM. Geographic distribution of wild poliovirus type 1
genotypes. Virology 1987 Oct; 160(2):311–22. PMID: 2821678
21. World Health Organization. Manual for the Virological Investigation of Polio. Geneva: World Health
Organization; 1997. 66 p.
22. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Anal-
ysis version 6.0. Molecular Biology and Evolution 2013 Dec; 30(12):2725–9. doi: 10.1093/molbev/
mst197 PMID: 24132122
23. Lentz KN, Smith AD, Geisler SC, Cox S, Buontempo P, Skelton A, et al. Structure of poliovirus type 2
Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological proper-
ties of three poliovirus serotypes. Structure 1997 Jul 15; 5(7):961–78. PMID: 9261087
24. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative pro-
tein modeling. Electrophoresis 1997 Dec; 18(15):2714–23. PMID: 9504803
25. Goldman N, Yang Z. A codon-based model of nucleotide substitution for protein-coding DNA
sequences. Mol Biol Evol 1994 Sep; 11(5):725–36. PMID: 7968486
26. Cai James J, Smith David K, Xia Xuhua, Yuen Kwok-yung. MBEToolbox: a Matlab toolbox for
sequence data analysis in molecular biology and evolution. BMC Bioinformatics 2005 Mar 22; 6:64.
PMID: 15780146
27. Tamura K. Estimation of the number of nucleotide substitutions when there are strong transition-trans-
version and G + C-content biases. Molecular Biology and Evolution 1992 Jul; 9(4):678–87. PMID:
1630306
28. Martin DP, Murrell B, Golden M, Khoosal A, & Muhire B. RDP4: Detection and analysis of recombina-
tion patterns in virus genomes. Virus Evolution 2015; 1:vev003.
Type 2 VDPV Isolated in Brazil
PLOS ONE | DOI:10.1371/journal.pone.0152251 March 28, 2016 15 / 18
29. PadidamM, Sawyer S, Fauquet CM. Possible emergence of new geminiviruses by frequent recombina-
tion. Virology 1999 Dec; 265(2):218–25. PMID: 10600594
30. Martin DP, Posada D, Crandall KA, Williamson C. A modified BOOTSCAN algorithm for automated
identification of recombinant sequences and recombination breakpoints. AIDS Res HumRetroviruses
2005 Jan; 21(1):98–102. PMID: 15665649
31. Posada D, Crandall KA. Evaluation of methods for detecting recombination from DNA sequences:
Computer simulations. Proc Natl Acad Sci 2001 Nov; 98(24):13757–62. PMID: 11717435
32. Maynard Smith J. Analyzing the mosaic structure of genes. J Mol Evol 1992 Feb; 34(2):126–9. PMID:
1556748
33. Gibbs MJ, Armstrong JS, Gibbs AJ. Sister-Scanning: a Monte Carlo procedure for assessing signals in
recombinant sequences. Bioinformatics 2000 Jul; 16(7):573–82. PMID: 11038328
34. Boni MF, Posada D, FeldmanMW. An exact nonparametric method for inferring mosaic structure in
sequence triplets. Genetics 2007 Jun; 176(2):1035–47. PMID: 17409078
35. Martin D, Rybicki E. RDP: detection of recombination amongst aligned sequences. Bioinformatics 2000
Jun; 16(6):562–3. PMID: 10980155
36. Liu X, Wu C, Chen A. Codon usage bias and recombination events for neuraminidase and hemaggluti-
nin genes in Chinese isolates of influenza A virus subtype H9N2. Arch Virol 2010 May; 155(5):685–93.
doi: 10.1007/s00705-010-0631-2 PMID: 20300785
37. Zhang Y, Yan D, Zhu S, Wen N, Li L, Wang H, et al. Type 2 vaccine-derived poliovirus from patients
with acute flaccid paralysis in China: current immunization strategy effectively prevented its sustained
transmission. J Infect Dis 2010 Dec 15; 202(12):1780–8. doi: 10.1086/657410 PMID: 21050127
38. Zhang Y, Wang H, Zhu S, Li Y, Song L, Liu Y, et al. Characterization of a rare natural intertypic type 2/
type 3 penta-recombinant vaccine-derived poliovirus isolated from a child with acute flaccid paralysis. J
Gen Virol 2010 Feb; 91(Pt 2):421–9. doi: 10.1099/vir.0.014258-0 PMID: 19846676
39. Yan D, Zhang Y, Zhu S, Chen N, Li X, et al. Limited and Localized Outbreak of Newly Emergent Type 2
Vaccine-Derived Poliovirus in Sichuan, China. Clin Vaccine Immunol 2014 Jul; 21(7):1012–8. doi: 10.
1128/CVI.00196-14 PMID: 24850620
40. Yang CF, Naguib T, Yang SJ, Nasr E, Jorba J, Ahmed N, et al. Circulation of endemic type 2 vaccine-
derived poliovirus in Egypt from 1983 to 1993. J Virol 2003 Aug; 77(15):8366–77. PMID: 12857906
41. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, Randriamanalina B, Guillot S, Bala-
nant J, et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis 2003 Jul; 9
(7):885–887. PMID: 12899139
42. Razafindratsimandresy R, Joffret L, Rabemanantsoa S, Andriamamonjy S, Heraud J, et al. (2013)
Reemergence of Recombinant Vaccine–derived Polioviruses in Healthy Children, Madagascar. Emerg
Infect Dis 2013 Jun; 19(6):1008–10. doi: 10.3201/eid1906.130080 PMID: 23735779
43. Burns CC, Shaw J, Jorba J, Bukbuk D, Adu F, Gumede N, et al. Multiple independent emergences of
type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J Virol 2013 May; 87
(9):4907–22. doi: 10.1128/JVI.02954-12 PMID: 23408630
44. Adu F, Iber J, Bukbuk, Gumede N, Yang SJ, Jorba J, et al. Isolation of recombinant type 2 vaccine-
derived poliovirus (VDPV) from a Nigerian child. Virus Res 2007 Jul; 127(1):17–25. PMID: 17449127
45. Shulman LM, Manor Y, Sofe D, Handsher R, Swartz T, Delpeyroux F, et al. Neurovirulent vaccine-
derived polioviruses in sewage from highly immune populations. PLoS One 2006 Dec 20; 1:e69. PMID:
17183700
46. Hovi T, Paananen A, Blomqvist S, Savolainen-Kopra C, Al-Hello H, Smura T, et al. Characteristics of
an Environmentally Monitored Prolonged Type 2 Vaccine Derived Poliovirus Shedding Episode that
Stopped without Intervention. PLoS One 2013 Jul 31; 8(7):e66849. doi: 10.1371/journal.pone.0066849
PMID: 23935826
47. Al-Hello H, Jorba J, Blomqvist S, Raud R, Kew O, Roivainen M. Highly Divergent Type 2 and 3 Vac-
cine-Derived Polioviruses Isolated from Sewage in Tallinn, Estonia. J Virol 2013 Dec; 87(23):13076–
80. doi: 10.1128/JVI.01174-13 PMID: 24049178
48. Nei M, Kumar S. Molecular Evolution and Phylogenetics. New York: Oxford University Press; 2000.
333 p.
49. Nakano JH, Milford MH, Thieme ML, Nottay B. Parameters for differentiating vaccine derived and wild
poliovirus strains. In: Melnick JL, editor. Progress in Medical Virology. New York: S. Karger; 1978. p.
178–206.
50. Böttiger M. Rct-marker tests on isolates fromWM 3 and Sabin type 3 attenuated poliovirus vaccines.
Archiv für die gesamte Virusforschung 1968 Sep; 25(3):299–307. PMID: 4303675
Type 2 VDPV Isolated in Brazil
PLOS ONE | DOI:10.1371/journal.pone.0152251 March 28, 2016 16 / 18
51. Pliaka V, Dedepsidis E, Kyriakopoulou Z, Papadi G, Tsakogiannis D, Pratti A, et al. Growth kinetic anal-
ysis of bi-recombinant poliovirus vaccine strains. Virus Genes 2010 Apr; 40(2):200–11. doi: 10.1007/
s11262-010-0448-9 PMID: 20091423
52. Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, Feldman E, et al. Retrospective
analysis of a local cessation of vaccination against poliomyelitis: a poliomyelitis: a possible scenario for
the future. J Virol 2003 Dec; 77(23):12460–5. PMID: 14610170
53. Ren RB, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related
type 2 poliovirus. J Virol 1991 Mar; 65(3):1377–82. PMID: 1847458
54. La Monica N, Meriam C, Racaniello VR. Mapping of sequences required for mouse neurovirulence of
poliovirus type 2 Lansing. J Virol 1986 Feb; 57(2):515–25. PMID: 3003384
55. Dragunsky EM, Ivanov AP, Wells VR, Ivshina AV, Rezapkin GV, Abe S, et al. Evaluation of immunoge-
nicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predict-
ing vaccine efficacy. J Infect Dis 2004 Oct; 190(8):1404–12. PMID: 15378432
56. Couderc T, Guinguene B, Horaud F, Aubert-Combiescu A, Crainic R. Molecular pathogenesis of type 2
poliovirus in mice. Eur J Epidemiol 1989 Sep; 5(3):270–4. PMID: 2551721
57. Goodfellow I, Chaudhry Y, Richardson A, Meredith J, Almond JW, et al. Identification of a cis-acting rep-
lication element within the poliovirus coding region. J Virol 2000 May; 74(10):4590–600. PMID:
10775595
58. Rieder E, Paul AV, Kim DW, van Boom JH, Wimmer E. Genetic and biochemical studies of poliovirus
cis-acting replication element cre in relation to VPg uridylylation. J Virol 2000 Nov; 74(22):10371–80.
PMID: 11044081
59. Brown B, Oberste MS, Maher K, Pallansch M. Complete genomic sequencing shows that poliovirus
and members of human enterovirus species C are closely related in the non-capsid coding region. J
Virol 2003 Aug; 77(16): 8973–8984. PMID: 12885914
60. Liu H-M, Zheng D-P, Zhang L-B, Oberste MS, Kew OM, Pallansch MA. Serial recombination during cir-
culation of type 1 wild-vaccine recombinant poliovirus in China. J Virol 2003 Oct; 77(20): 10994–
11005. PMID: 14512548
61. Jegouic S, Joffret M-L, Blanchard C, Riquet FB, Perret C, Pelletier I, et al. Recombination between
poliovirus and co-circulating Coxsackie A viruses: role in the emergence of pathogenic vaccine-derived
poliovirus. Plos Path 2009 May; 5(5):e1000412.
62. DeVries AS, Harper J, Murray A, Lexau C, Bahta L, Christensen J, et al. Vaccine-derived poliomyelitis
12 years after infection in Minessota. N Engl J Med 2011 Jun 16; 364(24):2316–23. doi: 10.1056/
NEJMoa1008677 PMID: 21675890
63. Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW, et al. Genetic basis of attenua-
tion of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 1993 Jan; 192(1):18–26. PMID:
8390752
64. Ren RB, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related
type 2 poliovirus. J Virol Mar; 65(3):1377–82.
65. Shulman LM, Handsher R, Yang CF, Yang SJ, Manor J, Vonsover A, et al. Resolution of the pathways
of poliovirus type 1 transmission during an outbreak. J Clin Microbiol. 2000 Mar; 38(3):945–52. PMID:
10698978
66. Minor PD, Dunn G. The effect of sequences in the 5' non-coding region on the replication of polioviruses
in the human gut. J Gen Virol 1988 May; 69 (Pt 5):1091–6. PMID: 2836553
67. Yakovenko ML, Cherkasova EA, Rezapkin GV, Ivanova OE, Ivanov AP, Eremeeva TP, et al. Antigenic
Evolution of Vaccine-Derived Polioviruses: Changes in Individual Epitopes and Relative Stability of the
Overall Immunological Properties. J Virol 2006 Mar; 80(6):2641–53. PMID: 16501074
68. Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T. Prevalence of vaccine-
derived polioviruses in the environment. J Gen Virol 2002 May; 83(Pt 5):1107–11. PMID: 11961265
69. Hovi T. Surveillance for polioviruses. Biologicals 2006 Jun; 34(2):123–6. PMID: 16678443
70. Gary HE, Sanders R, Pallansch MA. A theoretical framework for evaluating the sensitivity of surveil-
lance for detecting wild poliovirus: factors affecting detection sensitivity in a population with circulating
wild poliovirus. J Infect Dis 1997 Feb; 175 Suppl 1:S141–5. PMID: 9203706
71. Bottiger M, Herrstrom E. Isolation of polioviruses from sewage and their characteristics: experience
over two decades in Sweden. Scand J Infect Dis 1992; 24(2):151–5. PMID: 1322558
72. Deshpande JM, Shetty SJ, Siddiqui ZA. Environmental surveillance system to track wild poliovirus
transmission. Appl Environ Microbiol 2003 May; 69(5):2919–27. PMID: 12732567
Type 2 VDPV Isolated in Brazil
PLOS ONE | DOI:10.1371/journal.pone.0152251 March 28, 2016 17 / 18
73. Tao Z, Zhang Y, Liu Y, Xu A, Lin X, Yoshida H, et al. Isolation and Characterization of a type 2 vaccine-
derived poliovirus from environmental surveillance in China, 2012. Plos One 2013 Dec 26; 8(12):
e83975. doi: 10.1371/journal.pone.0083975 PMID: 24386319
Type 2 VDPV Isolated in Brazil
PLOS ONE | DOI:10.1371/journal.pone.0152251 March 28, 2016 18 / 18
